Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropeptides from motor nerve endings, but also connects sensory nerves to the central nervous system. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity, sensory disorders, bladder pain and pelvic pain, and inflammatory disorders of the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue of Toxins covers the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects.

urethra --- onabotulinumtoxinA --- voiding --- therapeutic outcome --- lower urinary tract symptoms --- botulinum toxin --- benign prostatic hyperplasia --- prostatitis --- inflammation --- Botulinum toxin --- chronic prostatitis --- interstitial cystitis --- treatment --- bladder pain --- botulinum toxin A --- predictor --- maximal bladder capacity --- hydrodistention --- urethral sphincter --- urethral sphincter dysfunction --- urodynamics --- drug delivery --- overactive bladder --- painful bladder syndrome --- molecular mechanism --- chronic pelvic pain syndrome --- pelvic pain --- functional urology disorder --- human --- network meta-analysis --- OnabotulinumtoxinA --- peripheral tibial nerve stimulation --- sacral neuromodulation --- bladder --- sensation --- therapy --- pathophysiology --- diabetes mellitus --- mid-urethral sling --- antimuscarinics --- urinary incontinence --- functional urological disorders --- pain --- neurogenic detrusor overactivity

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book collects 25 scientific articles from laboratories around the world, all of which use botulinum neurotoxins as the main protagonists of their studies. The use of botulinum neurotoxin in medicine, following its ability to inhibit the effects of various disorders of different etiology on the human organism, constitutes the main topic of each article presented here. This book, which is aimed at both students and medical professionals, attempts to summarize current knowledge about the use of botulinum toxin as a therapeutic agent in many diseases, ranging from spasticity to tremor, form motor dysfunction after stroke to neuropathic pain, from hyperactive muscle to migraine, and so on. Thanks to its simplified writing, accessible to an audience who may not be familiar with the mysteries of science, readers will get new insights into this biological toxin and its multiple applications, not simply relegated to its historical use to correct of face wrinkles. Both review and research articles are presented, not only concerning animal studies, but also clinical reports. This book will provide an up-to-date picture of the state-of-the-art of the possible development of novel applications of botulinum neurotoxins for future therapeutic purposes.

Medicine --- botulinum toxin --- limb tremors --- muscle selection --- biological effect --- various cell types --- neurotransmitter --- dermatology --- novel indication --- botulinum neurotoxin --- masticatory system --- maxillofacial bone --- dental occlusion --- orthognathic surgery --- sialorrhoea --- drooling --- salivary glands --- swallowing --- eccrine glands --- onabotulinumtoxin A --- incobotulinumtoxin A --- botulinum neurotoxins --- botulinum neurotoxin serotype A --- heavy chain --- botulinum neurotoxin serotype a heavy chain (BoNT/A HC) --- spinal cord injury (SCI) --- nerve regeneration --- growth associated protein 43 (GAP-43) --- superior cervical ganglion 10 (SCG10) --- neuronal processes --- neural regeneration --- Schwann cells --- glia --- spinal cord --- immunohistochemistry --- allodynia --- weight bearing --- sciatic static index --- walking track analysis --- itch --- SNARE --- VAMP --- mast cells --- compound 48/80 --- chloroquine --- spasticity --- botulinum toxin type A --- appropriate treatment --- Therapeutic Index --- pruritus --- antipruritic --- clinical --- experimental --- BoNT/A --- astroglia --- interleukins --- microglia --- TLR2 --- TLR4 --- Snap-23 --- pain --- cerebral palsy --- botulinum toxin A --- complex regional pain syndrome --- lumbar sympathetic ganglion block --- chronic pelvic pain --- overactive detrusor --- vaginism --- temporomandibular joint dislocation --- lateral pterygoid muscle --- botulinum toxin therapy --- synaptic transmission --- SNAP-25 --- epilepsy --- Parkinson's disease --- neurotransmission blockade --- electrical activity --- prion disease --- new indications --- formulation --- delivery --- refractory chronic migraine --- tension headache --- medication overuse headache --- prophylactic treatment --- XEOMIN® --- BTX --- central neuropathic pain --- spinal cord injury --- post-stroke shoulder pain --- mouse test --- Clostridium tetani --- botulinum antitoxin --- food safety --- abobotulinumtoxinA --- upper limb spasticity --- post-stroke --- early use --- ONTIME --- clinical trial --- human --- urodynamics --- botulinum neurotoxin-A --- basal ganglia --- interspecies differences in motor behavior --- mouse --- rat --- interneurons --- hand tremor --- treatment --- electromyography --- kinematics --- essential tremor --- dystonic tremor --- tremor --- movement disorders --- Botulinum toxin --- upper limb biomechanics --- joint biomechanics --- diagnostic guidance --- clinical decision support --- spastic paresis --- electrical stimulation --- stroke management --- rehabilitation --- hand --- botulinum toxin --- limb tremors --- muscle selection --- biological effect --- various cell types --- neurotransmitter --- dermatology --- novel indication --- botulinum neurotoxin --- masticatory system --- maxillofacial bone --- dental occlusion --- orthognathic surgery --- sialorrhoea --- drooling --- salivary glands --- swallowing --- eccrine glands --- onabotulinumtoxin A --- incobotulinumtoxin A --- botulinum neurotoxins --- botulinum neurotoxin serotype A --- heavy chain --- botulinum neurotoxin serotype a heavy chain (BoNT/A HC) --- spinal cord injury (SCI) --- nerve regeneration --- growth associated protein 43 (GAP-43) --- superior cervical ganglion 10 (SCG10) --- neuronal processes --- neural regeneration --- Schwann cells --- glia --- spinal cord --- immunohistochemistry --- allodynia --- weight bearing --- sciatic static index --- walking track analysis --- itch --- SNARE --- VAMP --- mast cells --- compound 48/80 --- chloroquine --- spasticity --- botulinum toxin type A --- appropriate treatment --- Therapeutic Index --- pruritus --- antipruritic --- clinical --- experimental --- BoNT/A --- astroglia --- interleukins --- microglia --- TLR2 --- TLR4 --- Snap-23 --- pain --- cerebral palsy --- botulinum toxin A --- complex regional pain syndrome --- lumbar sympathetic ganglion block --- chronic pelvic pain --- overactive detrusor --- vaginism --- temporomandibular joint dislocation --- lateral pterygoid muscle --- botulinum toxin therapy --- synaptic transmission --- SNAP-25 --- epilepsy --- Parkinson's disease --- neurotransmission blockade --- electrical activity --- prion disease --- new indications --- formulation --- delivery --- refractory chronic migraine --- tension headache --- medication overuse headache --- prophylactic treatment --- XEOMIN® --- BTX --- central neuropathic pain --- spinal cord injury --- post-stroke shoulder pain --- mouse test --- Clostridium tetani --- botulinum antitoxin --- food safety --- abobotulinumtoxinA --- upper limb spasticity --- post-stroke --- early use --- ONTIME --- clinical trial --- human --- urodynamics --- botulinum neurotoxin-A --- basal ganglia --- interspecies differences in motor behavior --- mouse --- rat --- interneurons --- hand tremor --- treatment --- electromyography --- kinematics --- essential tremor --- dystonic tremor --- tremor --- movement disorders --- Botulinum toxin --- upper limb biomechanics --- joint biomechanics --- diagnostic guidance --- clinical decision support --- spastic paresis --- electrical stimulation --- stroke management --- rehabilitation --- hand